Hepatitis C, chronic, Genotype 1, 2, 3, 4, 5, and 6.
Black Box Warning: Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Test for hepatitis B surface antigen and hepatitis B core antibody prior to initiation.
Monitor signs and symptoms of hepatitis flare or HBV reactivation during treatment and post-treatment follow-up in patients with evidence of current or prior HBV infection.
Monitor hepatic function at baseline and during treatment.
Common
Severe
Contraindication:
Major drug-drug interactions:
Antimicrobial class: Antiviral agent, HCV NS5A inhibitor (Pibrentasvir), HCV NS3/4A Protease Inhibitor (Glecaprevir)
Average serum half life: 6 hours (Glecaprevir), 13 hours (Pibrentasvir)
Precautions: Monitoring recommended and discontinuation may be necessary in cases of hepatic decompensation/failure without cirrhosis or with compensated cirrhosis, patients taking concomitant medications, or with confounding factors (e.g. liver-related medical or surgical comorbidities).
항생제
